Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS20040077988 A1
Publication typeApplication
Application numberUS 10/639,614
Publication dateApr 22, 2004
Filing dateAug 11, 2003
Priority dateAug 27, 1998
Also published asCA2341521A1, DE69922514D1, DE69922514T2, EP1107710A1, EP1107710B1, EP1516599A2, EP1516599A3, US6406488, US20020095111, US20060052736, WO2000012029A1
Publication number10639614, 639614, US 2004/0077988 A1, US 2004/077988 A1, US 20040077988 A1, US 20040077988A1, US 2004077988 A1, US 2004077988A1, US-A1-20040077988, US-A1-2004077988, US2004/0077988A1, US2004/077988A1, US20040077988 A1, US20040077988A1, US2004077988 A1, US2004077988A1
InventorsKatherine Tweden, Guy Vanney
Original AssigneeHeartstent Corporation
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Healing transmyocardial implant
US 20040077988 A1
Abstract
A transmyocardial implant establishes a blood flow path through a myocardium between a heart chamber and a lumen of a coronary vessel residing on an exterior of the heart. The implant includes a coronary portion sized to be received within the vessel. A myocardial portion is sized to pass through the myocardium into the heart chamber. A transition portion connects the coronary and myocardial portions for directing blood flow from the myocardial portion to the coronary portion. The coronary portion and the myocardial portion have an open construction for permitting tissue growth across a wall thickness of the coronary portion and the myocardial portion. The myocardial portion includes an agent for controlling a coagulation cascade and platelet formation.
Images(3)
Previous page
Next page
Claims(17)
What is claimed:
1. A transmyocardial implant for defining a blood flow pathway directly from a left ventricle to a coronary vessel, the implant comprising:
a coronary portion sized to be received within the vessel;
a myocardial portion sized to pass through the myocardium into the left ventricle;
a transition portion connecting the coronary and myocardial portion for directing blood flow from the myocardial portion to the coronary portion;
at least the coronary portion and the myocardial portion having an open construction for permitting tissue growth across a wall thickness of the coronary portion and the myocardial portion; and
at least the myocardial portion including an agent for controlling a coagulation cascade and platelet activation.
2. An implant according to claim 1 further comprising an agent for encouraging healing.
3. An implant according to claim 1 further comprising a porous lining in at least the myocardial portion with the porous lining have pores smaller than openings of the open construction of the myocardial portion.
4. An implant according to claim 1 wherein the porous lining contains the agent.
5. An implant according to claim 1 wherein the agent is heparin.
6. An implant according to claim 1 wherein the agent is an anti-coagulant.
7. An implant according to claim 1 wherein the agent is an anti-platelet.
8. An implant according to claim 2 wherein the agent for encouraging healing is a growth factor.
9. An implant according to claim 1 wherein the coronary portion is expandable from a first diameter to an enlarged second diameter.
10. An implant according to claim 1 wherein the myocardial portion is expandable from a first diameter to an enlarged second diameter.
11. An implant according to claim 1 wherein the transition portion permits articulation between the coronary portion and the myocardial portion.
12. A transmyocardial implant for defining a blood flow pathway directly from a left ventricle to a coronary vessel, the implant comprising:
a coronary portion sized to be received within the vessel;
a myocardial portion sized to pass through the myocardium into the left ventricle;
a transition portion connecting the coronary and myocardial portion for directing blood flow from the myocardial portion to the coronary portion; and
the myocardial portion including a construction to facilitate tissue integration and including an agent for controlling a coagulation cascade and platelet activation.
13. An implant according to claim 12 wherein the coronary portion includes an open structure to facilitate growth of vascular endothelial cells along the coronary portion.
14. An implant according to claim 12 wherein the myocardial portion includes a porous structure for facilitating growth of vascular endothelial cells into the myocardial portion.
15. An implant according to claim 14 wherein the porous structure includes a fabric liner.
16. An implant according to claim 14 wherein the myocardial portion further includes a wall structure for facilitating growth of structural cells into the interior of the myocardial portion.
17. An implant according to claim 16 wherein the wall structure is an open cell construction of the myocardial portion.
Description
    BACKGROUND OF THE INVENTION
  • [0001]
    1. Field of the Invention
  • [0002]
    This invention pertains to an implant for passing blood flow directly between a chamber of the heart and a coronary vessel. More particularly, this invention pertains to such an implant with an enhance design for promoting a healed layer of cells on an interior of the implant.
  • [0003]
    2. Description of the Prior Art
  • [0004]
    Commonly assigned U.S. Pat. No. 5,755,682 issued May 26, 1998 and commonly assigned and co-pending U.S. patent application Ser. No. 08/882,397 filed Jun. 25, 1997, entitled “Method and Apparatus for Performing Coronary Bypass Surgery”, and filed in the name of inventors Mark B. Knudson and William L. Giese (published as PCT International Application Publication No. WO 98/06356) both teach an implant for defining a blood flow conduit directly from a chamber of the heart to a lumen of a coronary vessel. In one embodiment, an L-shaped implant is received within a lumen of a coronary artery and passed through the myocardium to extend into the left ventricle of the heart. The conduit is rigid and remains open for blood flow to pass through the conduit during both systole and diastole. The conduit penetrates into the left ventricle in order to prevent tissue growth and occlusions over an opening of the conduit. The '682 patent and '397 application also describe an embodiment where a portion of the implant passing through the heart wall is an open structural member lined by polyester (e.g., Dacron). A further embodiment discloses a portion of the implant in a coronary vessel as being an open cell, balloon-expandable stent.
  • [0005]
    U.S. Pat. No. 5,429,144 to Wilk dated Jul. 4, 1995 teaches implants which are passed through the vasculature in a collapsed state and expanded when placed in the myocardium so as not to extend into either the coronary artery or the left ventricle. The described implants close once per cycle of the heart (e.g., during diastole in the embodiment of FIGS. 7A and 7B or during systole in the embodiment of FIGS. 2A and 2B). Either of these two designs may be lined with a graft.
  • [0006]
    Commonly assigned and co-pending U.S. patent application Ser. No. 08/944,313 filed Oct. 6, 1997, entitled “Transmyocardial Implant”, and filed in the name of inventors Katherine S. Tweden, Guy P. Vanney and Thomas L. Odland, teaches an implant such as that shown in the aforementioned '397 application and '682 patent with an enhanced fixation structure. The enhanced fixation structure includes a fabric surrounding at least a portion of the conduit to facilitate tissue growth on the exterior of the implant.
  • [0007]
    PCT International Application Publication No. WO 98/08456 describes a protrusive stent to form a passageway from the heart to a coronary vessel. The stent is described as wire mesh or other metal or polymeric material and may be self-expanding or pressure expandable. The application describes the stent may be covered by a partial or complete tubular covering of material including polyester, woven polyester, polytetraflouroethylene, expanded polytetraflouroethylene, polyurethane, silicone, polycarbonate, autologous tissue and xenograft tissue.
  • [0008]
    Biocompatibility is an important design feature. Solid metal implants are formed of material (e.g., titanium or pyrolytic carbon) with low incidents of thrombus and platelet activation. While such materials are proven in use in a wide variety of products (e.g., heart valve components), they do not facilitate full healing. By “healing”, it is meant that over time, the patient's cells grow over the material of the implant so that blood flowing through the implant is exposed only (or at least primarily) to the patient's cells rather than to a foreign material.
  • SUMMARY OF THE INVENTION
  • [0009]
    According to a preferred embodiment of the present invention, a transmyocardial implant is disclosed for establishing a blood flow path through a myocardium between a heart chamber and a lumen of a coronary vessel residing on an exterior of the heart. The implant includes a coronary portion sized to be received with the vessel. A myocardial portion is sized to pass through the myocardium into the heart chamber. A transition portion connects the coronary and myocardial portions for directing blood flow from the myocardial portion and into the coronary portion. The coronary portion and the myocardial portion have an open construction for permitting tissue growth across a wall thickness of the coronary portion and the myocardial portion. The myocardial portion includes an agent for controlling the coagulation cascade and platelet activation, and promoting healing.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • [0010]
    [0010]FIG. 1 is a side-elevation view of a transmyocardial implant according to the present invention shown in place defining a blood flow path from a left ventricle to a coronary artery;
  • [0011]
    [0011]FIG. 2 is a cross-sectional view of the implant of FIG. 1;
  • [0012]
    [0012]FIG. 3 is a view of an alternative embodiment of the implant of FIG. 1 illustrating a portion of the implant expandable within a coronary artery;
  • [0013]
    [0013]FIG. 4 is a view similar to FIG. 3 showing a transition portion of open cell construction;
  • [0014]
    [0014]FIG. 5 is a side section view of an alternative embodiment of FIG. 3 showing a balloon catheter admitted into the implant through an access port; and
  • [0015]
    [0015]FIG. 6 is a side sectional view of an expandable implant with a balloon catheter removable through a myocardial portion of the catheter.
  • DESCRIPTION OF THE PREFERRED EMBODIMENT
  • [0016]
    With initial reference to FIG. 1, a conduit 10 is shown in the form of an L-shaped tube. The conduit 10 may be formed of titanium or other biocompatible material. The material of the conduit 10 is preferably radially rigid material in order to withstand contraction forces of the myocardium. By way of non-limiting example, the tube will have an outside diameter DO of about 3 millimeters and an internal diameter DI of about 2.5 millimeters to provide a wall thickness of about 0.25 millimeters.
  • [0017]
    The tube 10 has a coronary portion 12 sized to be received within the lumen of a coronary vessel such as the lumen 80 of a coronary artery 82 distal to an obstruction 81 as illustrated in FIG. 1. The conduit 10 has a myocardial portion 14 extending at a right angle to the axis of portion 12. The myocardial portion 14 is sized to extend from the coronary artery 82 directly through the myocardium 84 and protrude into the left ventricle 83 of a patient's heart.
  • [0018]
    The coronary portion 12 has a first opening 16. The myocardial portion 14 has a second opening 18 in communication with an interior 20 of the implant 10. Therefore, blood can freely flow through the implant 10 between the left ventricle 83 and the lumen 80 of the coronary artery 82. Blood flows axially out of opening 16 parallel with the axis of lumen 80.
  • [0019]
    The longitudinal axis of the coronary portion 12 is aligned with the axis of the lumen 80. Sutures 24 secure the artery 82 to the coronary portion 12. The proximal portion 82 a of the coronary artery is ligated by sutures 85.
  • [0020]
    The coronary and myocardial portions 12, 14 have an open lattice construction 12 a, 14 a to define a plurality of open cells 12 b, 14 b extending through the wall thickness of the implant 10. Preferably, the coronary and myocardial portions 12, 14 are joined by a transition portion 13 in a 90 bend between portions 12, 14. While transition portion 13 can have an open lattice construction as portions 12, 14, transition portion 13 will preferably have smaller open areas in such an open construction or, as illustrated, will be of solid construction. Such construction permits the transition portion to deflect high velocity blood flows from the myocardial portion 14 into the coronary portion 12. A lattice construction with large open cells in the transition portion could result in the high velocity flow damaging tissue (not shown) overlying the transition portion.
  • [0021]
    Any one or all of the coronary portion 12, transition portion 13 and myocardial portion 14 could be formed in final size as rigid units or could be formed in small diameter sizes which are subsequently expanded to full size. For example, FIG. 3 illustrates a coronary portion 12′ which is formed tapering from the transition portion 13′ to a reduced diameter open end 16′. The taper permits ease of insertion into a coronary artery. Following such insertion, the tapered coronary portion 12′ may be expanded to full size illustrated by the phantom lines in FIG. 3. Such expansion can be performed using balloon-tipped catheters as is conventional in stent angioplasty. A collapsed and subsequently expanded implant 10 where all portions 12, 13 and 14 are expanded can permit use as a percutaneously deployed implant. The present drawings illustrate a presently preferred surgically deployed implant. In the surgical application, the artery 82 is ligated. The implant 10 is passed through the epicardium and myocardium on a side of the artery 82.
  • [0022]
    [0022]FIG. 5 illustrates a balloon 100 placed in a tapered coronary portion 12. A lead 102 from the balloon 100 is passed through an opening 113′ in the transition portion 13′. The opening 113′ can be closed with a plug 115′ after the balloon 100 and lead 102 are withdrawn through the opening 113′.
  • [0023]
    Alternatively, in a transition portion 13″ with open cell construction (FIG. 4), the balloon lead can be passed through the openings of the transition portion 113″. FIG. 6 illustrates passing the lead 102 through opening 18 of the myocardial portion. The lead 102 can be pulled upwardly from the exterior of the heart to remove the balloon 100. Alternatively, the lead 102 can be pulled through a catheter (not shown) adjacent end 18 in the left ventricle.
  • [0024]
    In either percutaneous or surgical implants, a flexible transition portion 13 (as would be achieved with a stent lattice construction) permits relative articulation between the coronary and myocardial portions 12, 14 to ensure the coronary portion is axially aligned with the lumen 80. Absent such articulation, such axial alignment is achieved by accurately controlling the position of the myocardial portion 14 such that the coronary portion 12 is axially aligned with the lumen 80 following implantation.
  • [0025]
    The open cell construction of the coronary and myocardial portions 12, 14 permit tissue growth through the open cells 12 c, 14 c following implant. The healing procedure in the coronary portion 12 is the same as that in coronary stents. Vascular endothelial cells grow over to coat the structural material 12 a of portion 12.
  • [0026]
    In portion 14, myocardial tissue, if not obstructed, will grow through the cells 14 c. Furthermore, the myocardium is highly thrombogenic. Therefore, uncontrolled contact between the myocardium 82 and the implant interior 20 can result in thrombosis of the implant 10. Further, it is believed that the epicardium (i.e., outer layer of the myocardium) has a greater density of myocardial growth cells which contribute to healing.
  • [0027]
    To control growth in the myocardial portion 14, a liner 30 is provided in the myocardial portion 14. The liner 30 is any porous material for accepting tissue growth and, preferably, is a polyester fabric (e.g., Dacron). The porous liner 30 has interstial spaces smaller than the open cells 12 c, 14 c. The liner 30 is shown on an interior of the myocardial portion 14 but could also or alternatively surround the exterior.
  • [0028]
    The liner 30 has an upper end 32 secured through any suitable means (e.g., sutures not shown) to the upper end of the myocardial portion 14. A lower end 34 is folded over the opening of the myocardial portion 14 and secured to the exterior of the portion 14 by sutures 36. The myocardial portion 14 is sized to protrude into the left ventricle 83 with only the folded over liner material exposed to the interior of the left ventricle 83.
  • [0029]
    The liner 30 acts as a porous substrate into which tissue may grow. To prevent thrombus, the liner 30 is impregnated with an agent for controlling coagulation cascade and platelet activation and adhesion. An example of such an agent is heparin but could be any anticoagulant or antiplatelet. Also, an agent such as a basic fibroblast growth factor could be used to accelerate healing.
  • [0030]
    The agent permits structural cells to grow on the liner by limiting thrombus formation which, uncontrolled, would occlude the implant. Due to the open construction, the structural, healing cells of the epicardium can grow onto the liner. Subsequently, endothelial cells can grow on the structural cells.
  • [0031]
    Therefore, the structure described promotes a three-stage healing process:
  • [0032]
    1. the drug agents control healing by minimizing coagulation and platelet activation which would otherwise be stimulated by agents from the myocardium; and
  • [0033]
    2. structural cells grow into and on the liner 30 now lined with the thrombus to initially heal and form a vascular bed; and
  • [0034]
    3. endothelial cells grow over the structural cells.
  • [0035]
    In the transition portion 13, an open cells structure will permit tissue growth as in the coronary portion 12. Such growth may also occur in the solid construction. Alternatively, the liner 30 can be extended into the transition portion 13. Additionally, the open cell structure in the transition portion 13 can permit articulation between the coronary portion and the myocardial portion. Such a structure is shown in FIG. 4. The open transition portion 13″ is formed by a coil 13 a″ between the coronary portion 12″ and the myocardial portion 14″. This structure permits bending at the transition portion. As a result, the coronary portion can be axially aligned in the artery without first accurately positioning the myocardial portion.
  • [0036]
    Having disclosed the present invention in a preferred embodiment, it will be appreciated that modifications and equivalents may occur to one of ordinary skill in the art having the benefits of the teachings of the present invention. It is intended that such modifications shall be included within the scope of the claims appended hereto. For example, the liner 30 can take many constructions including PTFE, expanded-PTFE, polyurethane, polypropylene or any biologically compatible paving material or natural tissue. Further, restenosis of the coronary portion 12 can be prevented with radioactivity therapy (such as providing the coronary portion with a short half-life beta emitter). Also, the liner 30 may be either a resorbable or non-resorbable material. Genetically engineered cells can be transformed to secrete anticoagulants and other agents to keep the blood fluid (such as tissue plasminogen activator and smooth muscle cells altered to express nitric acid).
Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US5123917 *Apr 27, 1990Jun 23, 1992Lee Peter YExpandable intraluminal vascular graft
US5287861 *Oct 30, 1992Feb 22, 1994Wilk Peter JCoronary artery by-pass method and associated catheter
US5389096 *Feb 25, 1993Feb 14, 1995Advanced Cardiovascular SystemsSystem and method for percutaneous myocardial revascularization
US5409019 *Nov 3, 1993Apr 25, 1995Wilk; Peter J.Coronary artery by-pass method
US5593434 *Jun 7, 1995Jan 14, 1997Advanced Cardiovascular Systems, Inc.Stent capable of attachment within a body lumen
US5618299 *Aug 8, 1995Apr 8, 1997Advanced Cardiovascular Systems, Inc.Ratcheting stent
US5637113 *Dec 13, 1994Jun 10, 1997Advanced Cardiovascular Systems, Inc.Polymer film for wrapping a stent structure
US5733267 *May 29, 1996Mar 31, 1998Scimed Life Systems, Inc.Pull back stent delivery system
US5755682 *Aug 13, 1996May 26, 1998Heartstent CorporationMethod and apparatus for performing coronary artery bypass surgery
US5758663 *Apr 5, 1996Jun 2, 1998Wilk; Peter J.Coronary artery by-pass method
US5855598 *May 27, 1997Jan 5, 1999Corvita CorporationExpandable supportive branched endoluminal grafts
US5871436 *Jul 19, 1996Feb 16, 1999Advanced Cardiovascular Systems, Inc.Radiation therapy method and device
US5873881 *Jul 12, 1996Feb 23, 1999Mcewen; James AllenLinear drive dermatome
US5876373 *Apr 4, 1997Mar 2, 1999Eclipse Surgical Technologies, Inc.Steerable catheter
US5878751 *Oct 20, 1997Mar 9, 1999Myocardial Stents, Inc.Method for trans myocardial revascularization (TMR)
US5885259 *Jul 17, 1997Mar 23, 1999Scimed Life Systems, Inc.Increasing radius curve catheter
US5908028 *Jul 11, 1997Jun 1, 1999Wilk Patent Development Corp.Coronary artery by-pass method
US5908029 *Aug 15, 1997Jun 1, 1999Heartstent CorporationCoronary artery bypass with reverse flow
US6010449 *Feb 28, 1997Jan 4, 2000Lumend, Inc.Intravascular catheter system for treating a vascular occlusion
US6026814 *Mar 6, 1997Feb 22, 2000Scimed Life Systems, Inc.System and method for percutaneous coronary artery bypass
US6029672 *Apr 20, 1998Feb 29, 2000Heartstent CorporationTransmyocardial implant procedure and tools
US6035856 *Mar 6, 1997Mar 14, 2000Scimed Life SystemsPercutaneous bypass with branching vessel
US6036677 *Jul 28, 1998Mar 14, 2000Cardiogenesis CorporationCatheter with flexible intermediate section
US6036697 *Jul 9, 1998Mar 14, 2000Scimed Life Systems, Inc.Balloon catheter with balloon inflation at distal end of balloon
US6045565 *Nov 2, 1998Apr 4, 2000Scimed Life Systems, Inc.Percutaneous myocardial revascularization growth factor mediums and method
US6053924 *Apr 29, 1999Apr 25, 2000Hussein; HanyDevice and method for trans myocardial revascularization
US6053942 *Aug 18, 1998Apr 25, 2000Heartstent CorporationTransmyocardial implant with coronary stent
US6056743 *Mar 5, 1998May 2, 2000Scimed Life Systems, Inc.Percutaneous myocardial revascularization device and method
US6067988 *Dec 26, 1996May 30, 2000Eclipse Surgical Technologies, Inc.Method for creation of drug delivery and/or stimulation pockets in myocardium
US6068638 *Oct 27, 1998May 30, 2000Transvascular, Inc.Device, system and method for interstitial transvascular intervention
US6071292 *Jun 28, 1997Jun 6, 2000Transvascular, Inc.Transluminal methods and devices for closing, forming attachments to, and/or forming anastomotic junctions in, luminal anatomical structures
US6076529 *Apr 20, 1998Jun 20, 2000Heartstent CorporationTransmyocardial implant with inserted vessel
US6080163 *Jun 15, 1998Jun 27, 2000Myocardial Stents, Inc.Device and method for trans myocardial revascularization (TMR)
US6080170 *Jan 19, 1999Jun 27, 2000Kensey Nash CorporationSystem and method of use for revascularizing stenotic bypass grafts and other occluded blood vessels
US6171251 *Jul 14, 1998Jan 9, 2001Eclipse Surgical Technologies, Inc.Method and apparatus for optimizing direct vessel implants for myocardial revascularization
US6186972 *Dec 9, 1998Feb 13, 2001James A. NelsonMethods and apparatus for treating ischemic heart disease by providing transvenous myocardial perfusion
US6190353 *Oct 11, 1996Feb 20, 2001Transvascular, Inc.Methods and apparatus for bypassing arterial obstructions and/or performing other transvascular procedures
US6193734 *Jan 5, 1999Feb 27, 2001Heartport, Inc.System for performing vascular anastomoses
US6197324 *Jul 15, 1998Mar 6, 2001C. R. Bard, Inc.System and methods for local delivery of an agent
US6200311 *Jan 20, 1998Mar 13, 2001Eclipse Surgical Technologies, Inc.Minimally invasive TMR device
US6203556 *Aug 5, 1999Mar 20, 2001Kensey Nash CorporationTransmyocardial revascularization system and method of use
US6213126 *Jun 19, 1997Apr 10, 2001Scimed Life Systems, Inc.Percutaneous artery to artery bypass using heart tissue as a portion of a bypass conduit
US6214041 *Jan 20, 1998Apr 10, 2001Heartstent CorporationTransmyocardial implant with septal perfusion
US6217549 *Sep 8, 1998Apr 17, 2001Lumend, Inc.Methods and apparatus for treating vascular occlusions
US6221049 *Oct 27, 1999Apr 24, 2001Lumend, Inc.Methods and apparatus for crossing vascular occlusions
US6223752 *Oct 27, 1998May 1, 2001Heartstent CorporationTransmyocardial implant procedure
US6224584 *May 4, 1999May 1, 2001Eclipse Surgical Technologies, Inc.Therapeutic and diagnostic agent delivery
US6231546 *Jan 13, 1998May 15, 2001Lumend, Inc.Methods and apparatus for crossing total occlusions in blood vessels
US6231587 *Mar 11, 1999May 15, 2001Transvascular, Inc.Devices for connecting anatomical conduits such as vascular structures
US6237607 *Nov 4, 1999May 29, 2001Heartstent CorporationTransmyocardial implant procedure
US6241667 *Jan 15, 1998Jun 5, 2001Lumend, Inc.Catheter apparatus for guided transvascular treatment of arterial occlusions
US6250305 *Jan 20, 1998Jun 26, 2001Heartstent CorporationMethod for using a flexible transmyocardial implant
US6251104 *Oct 31, 1997Jun 26, 2001Eclipse Surgical Technologies, Inc.Guiding catheter system for ablating heart tissue
US6251418 *Dec 18, 1997Jun 26, 2001C.R. Bard, Inc.Systems and methods for local delivery of an agent
US6350248 *Apr 13, 2000Feb 26, 2002Heartstent CorporationExpandable myocardial implant
US6361519 *Apr 13, 2000Mar 26, 2002Heartstent CorporationMesh tip myocardial implant
US6363939 *May 18, 1999Apr 2, 2002Wilk Patent Development Corp.Coronary artery by-pass method
US6375615 *Mar 31, 1999Apr 23, 2002Transvascular, Inc.Tissue penetrating catheters having integral imaging transducers and their methods of use
US6379319 *Oct 27, 1998Apr 30, 2002Transvascular, Inc.Systems and methods for directing and snaring guidewires
US6390098 *Dec 23, 1999May 21, 2002Scimed Life Systems, Inc.Percutaneous bypass with branching vessel
US6402740 *Jul 20, 2000Jun 11, 2002Scimed Systems, Inc.Expandable PMR device and method
US6406488 *Aug 27, 1998Jun 18, 2002Heartstent CorporationHealing transmyocardial implant
US6508825 *Sep 8, 1998Jan 21, 2003Lumend, Inc.Apparatus for treating vascular occlusions
US6511458 *Jan 19, 2001Jan 28, 2003Lumend, Inc.Vascular re-entry catheter
US6514217 *Apr 25, 2000Feb 4, 2003Lumend, Inc.Methods and apparatus for treating vascular occlusions
US6514271 *Feb 1, 2001Feb 4, 2003Kensey Nash CorporationTransmyocardial revascularization system and method of use
US6524323 *Jun 14, 2000Feb 25, 2003Kensey Nash CorporationSystem and method of use for revascularizing stenotic bypass grafts and other occluded blood vessels
US6544230 *Mar 31, 1999Apr 8, 2003Transvascular, Inc.Catheters, systems and methods for percutaneous in situ arterio-venous bypass
US6561998 *Apr 7, 1998May 13, 2003Transvascular, Inc.Transluminal devices, systems and methods for enlarging interstitial penetration tracts
US6565594 *Sep 24, 1997May 20, 2003Atrium Medical CorporationTunneling device
US6569147 *Sep 22, 2000May 27, 2003Kensey Nash CorporationSystems and methods of use for delivering beneficial agents for revascularizing stenotic bypass grafts and other occluded blood vessels and for other purposes
US6575168 *Jan 12, 2001Jun 10, 2003Scimed Life Systems, Inc.System and method for percutaneous coronary artery bypass
US6579311 *Jan 31, 1997Jun 17, 2003Transvascular, Inc.Method for interstitial transvascular intervention
US6685648 *Apr 3, 2001Feb 3, 2004Transvascular, Inc.Systems and methods for delivering drugs to selected locations within the body
US6709444 *May 17, 2001Mar 23, 2004Transvascular, Inc.Methods for bypassing total or near-total obstructions in arteries or other anatomical conduits
US6726677 *Mar 29, 2000Apr 27, 2004Transvascular, Inc.Stabilized tissue penetrating catheters
US20020002349 *Apr 3, 2001Jan 3, 2002Transvascular, Inc.Systems and methods for delivering drugs to selected locations within the body
US20020029079 *Jul 24, 2001Mar 7, 2002Transvascular, Inc.Devices for forming and/or maintaining connections between adjacent anatomical conduits
US20020049486 *Apr 30, 2001Apr 25, 2002Heartstent CorporationMethod and apparatus for performing coronary artery bypass surgery
US20020062146 *Nov 26, 2001May 23, 2002Joshua MakowerMethods and apparatus for transmyocardial direct coronary revascularization
US20020065478 *Jan 9, 2002May 30, 2002Heartstent CorporationMethod and apparatus for revascularizing a coronary vessel with an implant having a tapered myocardial leg
US20020072699 *Feb 15, 2002Jun 13, 2002Heartstent CorporationTransmyocardial implant with improved flow
US20020077566 *Oct 13, 1998Jun 20, 2002Gilbert S. LaroyaPlacing a guide member into a heart chamber through a coronary vessel and delivering devices for placing the coronary vessel in communication with the heart chamber
US20020077654 *May 11, 2001Jun 20, 2002Eclipse Surgical TechnologiesCatheter with flexible intermediate section
US20030018379 *Sep 17, 2002Jan 23, 2003Heartstent CorporationMethod and apparatus for performing coronary artery bypass surgery
US20030044315 *Sep 30, 2002Mar 6, 2003Peter BoekstegersMethod and device for the selective perfusion of fluids through blood vessels, controlled by the pressure in the blood vessels
US20030045828 *Jun 20, 2002Mar 6, 2003Wilk Peter J.Left ventricular conduits to coronary arteries and methods for coronary bypass
US20030055371 *Aug 15, 2002Mar 20, 2003Percardia, Inc.Left ventricular conduits to coronary arteries and methods for coronary bypass
US20030073973 *Nov 21, 2002Apr 17, 2003Kensey Nash CorporationTransmyocardial revascularization system and method of use
US20030120195 *Dec 3, 2002Jun 26, 2003Lumend, Inc.Re-entry catheter
US20040015225 *Jul 9, 2003Jan 22, 2004Kim Steven W.Deformable scaffolding multicellular stent
US20040019348 *May 21, 2003Jan 29, 2004Stevens John H.Method and apparatus for thoracoscopic intracardiac procedures
US20040059280 *Apr 29, 2003Mar 25, 2004Trans Vascular, Inc.Methods and apparatus for bypassing arterial obstructions and/or performing other transvascular procedures
US20040073157 *Oct 9, 2003Apr 15, 2004Heartstent CorporationMethod and apparatus for performing coronary artery bypass surgery
US20040073238 *Apr 29, 2003Apr 15, 2004Transvascular, Inc.Device, system and method for interstitial transvascular intervention
US20040077987 *Dec 10, 2003Apr 22, 2004Ventrica, Inc., Corporation Of DelawareDelivering a conduit into a heart wall to place a coronary vessel in communication with a heart chamber and removing tissue from the vessel or heart wall to facilitate such communication
US20040077990 *Oct 10, 2003Apr 22, 2004Heartstent CorporationMethod and apparatus for revascularizing a coronary vessel with an implant having a tapered myocardial leg
US20040088042 *Oct 27, 2003May 6, 2004Transvascular, Inc.Devices for forming and/or maintaining connections between adjacent anatomical conduits
US20040122318 *Nov 14, 2003Jun 24, 2004Transvascular, Inc.Tissue penetrating catheters having integral imaging transducers and their methods of use
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US7704222Aug 30, 2004Apr 27, 2010Jenavalve Technology, Inc.Methods and conduits for flowing blood from a heart chamber to a blood vessel
US7736327May 9, 2008Jun 15, 2010Jenavalve Technology, Inc.Methods and conduits for flowing blood from a heart chamber to a blood vessel
US8070708 *Feb 3, 2005Dec 6, 2011V-Wave LimitedDevice and method for controlling in-vivo pressure
US8091556Apr 20, 2001Jan 10, 2012V-Wave Ltd.Methods and apparatus for reducing localized circulatory system pressure
US8156942 *Dec 14, 2009Apr 17, 2012Medtronic Vascular, Inc.Method of implanting a transmyocardial stent
US8216174Apr 30, 2010Jul 10, 2012Jenavalve Technology, Inc.Methods and conduits for flowing blood from a heart chamber to a blood vessel
US8235933May 13, 2011Aug 7, 2012V-Wave Ltd.Methods and apparatus for reducing localized circulatory system pressure
US8328751May 13, 2011Dec 11, 2012V-Wave Ltd.Methods and apparatus for reducing localized circulatory system pressure
US8597226Jun 12, 2012Dec 3, 2013Jenavalve Technology, Inc.Methods and conduits for flowing blood from a heart chamber to a blood vessel
US8696611May 16, 2011Apr 15, 2014V-Wave Ltd.Device and method for regulating pressure in a heart chamber
US9034034Jul 28, 2011May 19, 2015V-Wave Ltd.Devices for reducing left atrial pressure, and methods of making and using same
US9629715Jul 28, 2011Apr 25, 2017V-Wave Ltd.Devices for reducing left atrial pressure having biodegradable constriction, and methods of making and using same
US9681948Jan 23, 2007Jun 20, 2017V-Wave Ltd.Heart anchor device
US9707382Mar 27, 2014Jul 18, 2017V-Wave Ltd.Device and method for regulating pressure in a heart chamber
US9713696May 20, 2014Jul 25, 2017V-Wave Ltd.Apparatus and methods for delivering devices for reducing left atrial pressure
US9724499May 16, 2011Aug 8, 2017V-Wave Ltd.Device and method for controlling in-vivo pressure
US20020099404 *Jan 25, 2001Jul 25, 2002Mowry David H.Intravascular ventriculocoronary artery bypass delivery modalities
US20020173742 *Apr 20, 2001Nov 21, 2002Gad KerenMethods and apparatus for reducing localized circulatory system pressure
US20030105514 *Jan 10, 2003Jun 5, 2003Percardia, Inc.Designs for left ventricular conduit
US20030135260 *Jan 16, 2002Jul 17, 2003Kohler Robert EdwardEncased implant and methods
US20030158509 *Feb 13, 2002Aug 21, 2003Tweden Katherine S.Cardiac implant and methods
US20040186507 *Jul 24, 2003Sep 23, 2004Percardia, Inc.Stent delivery system and method of use
US20060112956 *Oct 24, 2003Jun 1, 2006Michel SerpelloniUse of branched malto-dextrins as granulation binders
US20070282157 *Mar 2, 2005Dec 6, 2007Atria Medical Inc.Device And Method For Controlling In-Vivo Pressure
US20100094397 *Dec 14, 2009Apr 15, 2010Medtronic Vascular, Inc.Method of Implanting a Transmyocardial Stent
US20110218477 *May 13, 2011Sep 8, 2011V- Wave Ltd.,Methods and apparatus for reducing localized circulatory system pressure
US20110218481 *May 16, 2011Sep 8, 2011Dan RottenbergDevice and method for controlling in-vivo pressure
Classifications
U.S. Classification604/8
International ClassificationA61L33/10, A61L27/00, A61F2/82, A61F2/06, A61F2/94, A61B17/04, A61B17/11, A61B17/00, A61F2/02, A61F2/00
Cooperative ClassificationA61F2/915, A61B2017/00252, A61F2220/0008, A61F2/958, A61B17/11, A61F2/06, A61B17/04, A61F2002/828, A61F2/064, A61F2/07, A61F2/2493, A61F2/94, A61F2002/91533, A61F2230/0054, A61F2250/0067, A61F2002/91558, A61F2002/9155, A61F2/91
European ClassificationA61F2/24Y, A61F2/06, A61F2/91, A61F2/915, A61F2/06C, A61F2/94
Legal Events
DateCodeEventDescription
Dec 3, 2003ASAssignment
Owner name: PERCARDIA INC., NEW HAMPSHIRE
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HEARTSTENT CORPORATION;REEL/FRAME:014762/0323
Effective date: 20031024
Oct 3, 2006ASAssignment
Owner name: HORIZON TECHNOLOGY FUNDING COMPANY LLC, CONNECTICU
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PERCARDIA, INC.;REEL/FRAME:018375/0912
Effective date: 20060701